EGFR mutation is the most common oncogenic change found in non-small cell lung cancers (NSLC) (including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) [55], and anti-EGFR therapy is used in the treatment of NSLC [56]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.